MedTrace Logo

OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study

NCT00134160 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2010-10-05

No results posted yet for this study

Summary

The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive patients not adequately controlled by standard dose ARB alone.

Conditions

Interventions

DRUG

Olmesartan medoxomil

Olmesartan medoxomil 40mg/Day

DRUG

Calcium channel blockers (amlodipine, azelnidipine)

Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)

Sponsors & Collaborators

  • Japan Heart Foundation

    collaborator OTHER

  • OSCAR Study

    lead OTHER

Principal Investigators

  • Kikuo Arakawa, MD · Emeritus Professor Fukuoka University, Fukuoka, Japan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00134160 on ClinicalTrials.gov